VerifyNow® Clinical Compendium

This VerifyNow Compendium includes peer-reviewed journal publications which will provide you with additional education on the effective use of VerifyNow Antiplatelet Testing, as well as support the value of ongoing use of testing in clinical practice.

Our goal is to provide you with knowledge of the vast number of clinical publications that have been completed using VerifyNow testing with antiplatelet medications such as clopidogrel (or other P2Y12 inhibitors), Aspirin or GP IIb/IIIa inhibitors such as abciximab, or eptifibatide.

- Aspirin Test .............................................. Page 2
- IIb/IIIa Test ................................................ Page 15
- PRU/P2Y12 Test ........................................... Page 20
- Supporting Clinical Guidelines ..................... Page 53


Bouman HJ, van Werkum JW, Bret NJ, ten Cate H, Hackeng CM, ten Berg JM. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. 2011 Jun;97(12):983-90.


Peer-Reviewed Publications Citing the VerifyNow Assay Aspirin Test


Peer-Reviewed Publications Citing the VerifyNow Assay


Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, Kristensen SD. A comparison of platelet
function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Harrison P, Segal H, Silver L, Syed A, Cuthbertson FC, Rothwell PM. Lack of reproducibility of assessment of aspirin

Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient
ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005
May;36(5):1001-5.


Hobson AR, Petley G, Morton G, Dawkins KD, Curzen NP. Point-of-care platelet function assays demonstrate reduced
responsiveness to clopidogrel, but not aspirin, in patients with drug-eluting stent thrombosis whilst on dual antiplatelet therapy.

Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet

Huczek Z, Filipiak KJ, Kochman J, Michalak M, Grabowski M, Opolski G. Increased risk of minor bleeding and antiplatelet

size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual

Jeon SB, Song HS, Kim BJ, Kim HJ, Kang DW, Kim JS, Kwon SU. Biochemical aspirin resistance and recurrent lesions in

Jeong YH, Park Y, Bliden KP, Tantry US, Gurbel PA. High platelet reactivity to multiple agonists during aspirin and clopidogrel
treatment is indicative of a global hyperreactive platelet phenotype. Heart 2012;98:343.

Sep;52(8):1207-18.

Dec;75(6):990-4.

Lack of association between low density lipoprotein particle size and on-treatment platelet reactivity in patients with coronary


**Peer-Reviewed Publications Citing the VerifyNow Assay Aspirin Test**


Aspirin Test


Serebruany VL, Malinin AL, Pokov AN, Hanley DF. Antiplatelet Profiles of the Fixed-Dose Combination of Extended-Release Dipyridamole and Low-Dose Aspirin Compared with Clopirogrel With or Without Aspirin in Patients with Type 2 Diabetes and a History of Transient Ischemic Attack: A Randomized, Single Blind, 30-Day Trial. Clinical Therapeutics. 2008 30(2):249-59.


Swaim L, Hillman RS. Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study. J Thromb Thrombolysis. 2009 Jul;28(1):94-100.


Peer-Reviewed Publications Citing the VerifyNow IIb/IIIa Test


Peer-Reviewed Publications Citing the VerifyNow Assay

**IIb/IIIa Test**


Michelson AD. Methods for the measurement of platelet function. Review. Am J Cardiol. 2009 Feb 2;103(3 Suppl):20A-26A.


Peer-Reviewed Publications Citing the VerifyNow PRU Test / P2Y12 Test


Alexopoulos D. Regarding the “Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study”. Am Heart J 2012;163:e31.


**Peer-Reviewed Publications Citing the VerifyNow Assay**

**PRU Test / P2Y12**


Peer-Reviewed Publications Citing the VerifyNow Assay


Kalantzi KI, Dimitriou AA, Goudevenos JA, Tselepis AD. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment. Platelets. 2012;23(2):121-31.


Supporting Clinical Guidelines

